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Abstract—The assessment of medical practice is evolving rapidly in the United States. An initial focus on structure and process performance
measures assessing the quality of medical care is now being supplemented with efficiency measures to quantify the “value” of healthcare delivery.
This statement, building on prior work that articulated standards for publicly reported outcomes measures, identifies preferred attributes for
measures used to assess efficiency in the allocation of healthcare resources. The attributes identified in this document combined with the
previously published standards are intended to serve as criteria for assessing the suitability of efficiency measures for public reporting. This
statement identifies the following attributes to be considered for publicly reported efficiency measures: integration of the quality and cost; valid
cost measurement and analysis; minimal incentive to provide poor quality care; and proper attribution of the measure. The attributes described
in this statement are relevant to a wide range of efforts to profile the efficiency of various healthcare providers, including hospitals, healthcare
systems, managed-care organizations, physicians, group practices, and others that deliver coordinated care. (J Am Coll Cardiol 2008;52:1518 –26)
T he assessment of medical practice is evolving rapidly inthe United States. An initial focus on structure and
process performance measures to assess the quality of med-
ical care is now being supplemented with efficiency measures
to quantify the value of healthcare delivery. To address the
need for standards to govern these efforts, the American
Heart Association convened an interdisciplinary expert writ-
ing group to identify the essential attributes of measures
intended for public reporting of efficiency associated with the
delivery of care for patients with cardiovascular disease or
stroke. These attributes provide a framework for the devel-
opment and assessment of efficiency measures.
To date, enthusiasm for measuring and improving effi-
ciency is not matched by a consensus regarding the essential
attributes of measures that emphasize efficiency in the allo-
cation of healthcare resources. Reflecting the lack of a
common definition of efficiency, current efforts vary from
simply measuring and publicly reporting costs, which are not
measures of efficiency, to more sophisticated measures that
combine aspects of cost and quality. For the purpose of this
The American Heart Association and the American College of Cardiology Foundation make every effort to avoid any actual or potential conflicts of
interest that may arise as a result of an outside relationship or a personal, professional, or business interest of a member of the writing panel. Specifically,
all members of the writing group are required to complete and submit a Disclosure Questionnaire showing all such relationships that might be perceived
as real or potential conflicts of interest.
This statement was approved by the American Heart Association Science Advisory and Coordinating Committee on May 30, 2008, and by the
American College of Cardiology Foundation Board of Trustees on June 27, 2008.
The American College of Cardiology Foundation requests that this document be cited as follows: Krumholz HM, Keenan PS, Brush JE Jr, Bufalino
VJ, Chernew ME, Epstein AJ, Heidenreich PA, Ho V, Masoudi FA, Matchar DB, Normand S-LT, Rumsfeld JS, Schuur JD, Smith SC Jr, Spertus JA,
Walsh MN. Standards for measures used for public reporting of efficiency in health care: a scientific statement from the American Heart Association
Interdisciplinary Council on Quality of Care and Outcomes Research and the American College of Cardiology Foundation. J Am Coll Cardiol 2008;52:1518 –26.
This article is copublished in Circulation.
Copies: This document is available on the World Wide Web sites of the American Heart Association (my.americanheart.org) and the American College
of Cardiology (www.acc.org). For copies of this document, please contact Elsevier Inc. reprint department, fax (212) 633-3820, e-mail
reprints@elsevier.com.
Expert peer review of AHA Scientific Statements is conducted at the AHA National Center. For more on AHA statements and guidelines development,
visit http://www.americanheart.org/presenter.jhtml?identifier3023366.
Permissions: Multiple copies, modification, alteration, enhancement, and/or distribution of this document are not permitted without the express
permission of the American College of Cardiology Foundation or the American Heart Association. Please contact Elsevier’s permission department at
healthpermissions@elsevier.com.
Journal of the American College of Cardiology Vol. 52, No. 18, 2008
© 2008 by the American Heart Association, Inc. and the American College of Cardiology Foundation ISSN 0735-1097/08/$34.00
Published by Elsevier Inc. 10.1016/j.jacc.2008.09.004
statement, we focus on measures or combinations of mea-
sures that are specifically intended to convey information
about the efficient use of healthcare resources, incorporating
considerations of both the cost and quality of patient care. The
concept of efficiency is distinct from cost alone in that efficiency
takes into consideration the results produced, as well as the
resources used. Cost implies only consideration of resources
expended. Quality includes consideration of what is produced in
the way of care or outcomes. We therefore assume that effi-
ciency measures for public reporting should convey a balance of
information about resource use and clinical performance or
results that extends beyond a narrow focus on cost alone. The
idea is to convey information about areas in which low cost and
high quality are achieved and to provide a more complete
perspective on performance in cost as it relates to quality.
The present statement, which builds on prior work that
articulated standards for publicly reported outcomes mea-
sures (1), identifies preferred attributes for measures used to
assess efficiency in the allocation of healthcare resources.
Each of these attributes is, by design, under the control of the
measure developers. The attributes identified in the present
document, combined with the previously published standards,
are intended to guide measure development and serve as
criteria for assessing the suitability of efficiency measures for
public reporting. The authors of the present document include
individuals with expertise in clinical cardiology, quality of
care, economics, outcomes research, statistics, health services
research, epidemiology, healthcare policy, clinical perfor-
mance measurement, and public reporting.
Background
Cardiovascular disease and stroke are central to consider-
ations of the efficiency of care because they account for
disproportionate disease-related morbidity, mortality, and
cost (2). Cardiovascular services accounted for the greatest
share of the total change in healthcare spending from 1987 to
2002, far exceeding mental disorders, the next largest diag-
nostic group (3). The rise in cost per treated heart disease case
accounted for 70% of the rise in overall medical care
spending between 1987 and 2002.
In recognition of the lack of standardized approaches,
several organizations, including the National Quality Forum
(NQF) and the AQA (formerly Ambulatory Care Quality)
Alliance, are attempting to develop working definitions of
efficiency in health care so that efficiency at the level of the
clinician or institution can be measured objectively (4,5). The
AQA Alliance agenda includes 6 priority conditions, includ-
ing 3 cardiovascular conditions (acute myocardial infarction,
congestive heart failure, and coronary artery disease). Fur-
thermore, quality consortia have extended their scope of work
to cover measures that include some consideration of cost.
For example, the Leapfrog Hospital Insights program, which
has been adopted by hospitals throughout the United States,
included 2 measures that are related to cost (average length of
stay and readmissions) (6).
Federal and state programs are also developing various
approaches to address both cost and quality considerations in
measures initiatives. In August 2006, President Bush issued
an executive order to “Promote Quality and Efficient Health
Care in Federal Programs” that called for greater measure-
ment and new models of reimbursement that reward perfor-
mance (7). The Centers for Medicare & Medicaid Services
(CMS) has stated its goal of improving and reducing variation
in efficiency (8). CMS has developed an NQF-approved
measure of readmission after hospitalization for heart failure
(9). The Medicare Payment Advisory Commission’s June
2007 report to Congress, Promoting Greater Efficiency in
Medicare, contains several recommendations regarding effi-
ciency, including measuring hospital readmissions and re-
warding hospitals with low readmission rates (10). Readmis-
sion rates could be considered to reflect efficiency because a
readmission may represent a preventable adverse outcome
that is due to poor-quality care and is associated with higher
healthcare cost. States have initiated programs that are
purported to measure and report on the efficiency of care,
although efforts to date are heterogeneous and focus predom-
inantly on cost. At least 30 states have pending or enacted
legislation that requires disclosure, transparency, or publica-
tion of hospital and healthcare charges and fees (11). Several
states are reporting measures of resource use such as average
length of stay or insurer payments in conjunction with
measures of clinical quality (12,13).
Concurrent with these public efforts, private sector initia-
tives have proliferated under the direction of insurers and
consortia of purchasers. Many insurers are measuring the cost
of procedures, and admissions at different hospitals and by
different providers, and publishing this information online for
plan enrollees to view (14 –17). To date, there is wide
variation in the content and attributes of these measures, some
of which are cost-only measures and therefore not true
efficiency measures. The marked variability in development
of measures from multiple sectors further reinforces the need
to define the attributes of efficiency measures regarding
suitability for public reporting.
Attributes of Efficiency Measures
We introduce the following domains of attributes to be
considered for publicly reported efficiency measures (Table
1): Integration of quality and cost; valid cost measurement
and analysis; minimal incentive to provide poor-quality care;
and proper attribution of the measure. The attributes de-
scribed in the present statement are relevant to a wide range
of efforts to profile the efficiency of various healthcare
providers, including hospitals, healthcare systems, managed-
care organizations, physicians, group practices, and others
who deliver coordinated care. Ideally, all efficiency measures
Table 1. Standards for Measures Used for Public Reporting of
Efficiency in Health Care
Standard
Integration of quality and cost
Valid cost measurement and analysis
No or minimal incentive to provide poor-quality care
No or proper attribution of the measure
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would, at a minimum, possess these attributes for them to be
suitable for public reporting. The authors recognize that
measures may conform with several of these attributes to a
varying degree, and judgment will need to be applied to
determine whether they are suitable efficiency measures.
However, measures that only include cost (without any
pairing with what is produced), use invalid cost measures,
provide incentives for poor-quality care, or cannot be attrib-
uted properly should not be considered for public reporting.
For all measures, the degree of compliance with each of these
attributes should be clear.
These attributes are intended to be considered in addition
to those that were published previously for the public report-
ing of outcomes measures (1), which include the following:
1) the clear and explicit definition of an appropriate patient
sample; 2) clinical coherence of the variables used in statis-
tical models; 3) sufficiently high-quality and timely data;
4) designation of an appropriate reference time before which
covariates are derived and after which outcomes are mea-
sured; 5) use of an appropriate outcome and a standardized
period of outcome assessment; 6) application of an analytical
approach that accounts for the multilevel structure of data;
and 7) disclosure of the methods used to compare outcomes,
including disclosure of performance of the risk-adjustment
methodology in derivation and validation samples. An under-
lying assumption is that measures include risk adjustment or
a suitable explanation for why it is not necessary.
Integration of Quality and Cost
Any measure of efficiency that is suitable for public reporting
should explicitly include consideration of cost/resource use
and clinical outputs (eg, quality of care). The incorporation of
cost/resource use is fundamental to efficiency measures.
Focusing solely on resource considerations, however, fails to
account for the consequences; in some cases, providers may
achieve efficiency by offering comparably excellent care at
lower cost, but in others, lower cost may be associated with
underuse of key strategies or misallocation of inputs and
results in notably worse outcomes. Only by combining
measures of costs and outcomes is it possible to determine the
return on, or value of, the healthcare investment. Outcomes in
this sense can be understood as the experience of patients in
their interaction with the healthcare system and can include
clinical events, satisfaction, and intermediate events. Some
measures may include outcomes implicitly, such as those that
measure practices that increase cost and diminish outcomes
(eg, the use of inappropriate procedures that lead to risks that
outweigh benefits) or decrease cost and improve outcomes
(eg, certain disease management programs for patients with
heart failure), but situations in which there are potential
tradeoffs between cost and quality require explicit consider-
ation of both aspects of care.
A measure of cost or resource use alone provides only a
limited perspective on the true economic performance of the
system and may produce a misleading result. For example,
measuring the crude average cost of a percutaneous coronary
intervention provides no information about whether the sys-
tem is efficient. Procedures at one institution may cost less
than benchmarks for those procedures, but they may be
performed for the patients least likely to benefit from them.
For example, it is possible that an institution that is treating
many low-risk, asymptomatic patients who would receive
little to no clinical benefit from the procedure would have a
lower average cost than another institution that reserves the
procedure for higher-risk, symptomatic patients who would
be expected to derive greater benefit. Even the use of risk
adjustment in this hypothetical example would not account
for the fact that many of the patients in the lower-cost
institution should not have had the procedure performed. For
these patients, the yield from the cost investment is minimal
or nonexistent. Inclusion of the cost with the benefit from the
patient perspective will better provide a measure that can be
used to improve healthcare delivery. Thus, measures of costs
or resource use alone, although commonly referred to as
measures of efficiency, are not appropriate individual mea-
sures because they do not incorporate the perspective of what
is produced for the cost or whether the costs are directed in
the proper way.
Sometimes, surrogates for costs are used, but if used alone,
they can also be misleading. For example, length of stay is
more analogous to a cost measure than an efficiency measure.
Similarly, cost per admission is not an efficiency measure
because there is no measure of the quality or outcome
associated with the admission or its appropriateness. Al-
though the cost per admission may be a useful measure in
concert with other measures of what occurs within the
admission and afterward, in isolation it does not convey
efficiency without an implicit or explicit judgment about the
quality of the admission.
The combined consideration of costs and quality also
facilitates the identification of waste, those areas in which
higher costs do not produce meaningful increases in quality
or better outcomes (or may even worsen care and outcomes).
These areas are the best targets for improving the efficiency
of the healthcare system, because their elimination saves
money and may improve care and outcomes. The goals in this
case are not to minimize costs for wasteful activities but to
avoid them. For example, the American College of Cardiol-
ogy Foundation is publishing appropriateness criteria for
many cardiovascular diagnostic tests, including nuclear im-
aging, echocardiography, and computed tomography/mag-
netic resonance imaging, identifying situations for which
there was consensus that imaging did not benefit the patient
(18 –20). A measure that reports rates of inappropriate imag-
ing within practices would contain information regarding
both cost and quality, because an inappropriate test results in
both higher costs and poorer-quality care. Conversely, a
reduction in this rate would simultaneously improve quality
and decrease cost. Improvements in this metric should im-
prove the efficiency of the system. Given the importance of
this issue, measures of efficiency should clearly state how the
dimension of quality relates to cost. Moreover, the method of
assessment of quality should be clear, and the implications for
providing higher-quality care for a higher cost should be
transparent.
1520 Krumholz et al. JACC Vol. 52, No. 18, 2008
Standards for Measures: Efficiency in Health Care October 28, 2008:1518–26
Valid Cost Measurement and Analysis
Costs and quality should ideally be assessed concurrently and
with valid methods in the same population to provide an
accurate assessment of efficiency. Prior work has detailed the
characteristics of quality measures (21). Several specific
issues are important for the cost/resource assessment and are
highlighted in this section. The intent is not to define criteria
as much as to make clear what information needs to be
highlighted and justified.
Fundamental to cost assessment is a clear description of the
case identification and the episode of care that is included.
The perspective of the cost/resource assessment also needs to
be described explicitly. What could be conceived as efficient
from the perspective of a hospital that derives additional
revenue from each admission may be extremely inefficient
from the perspective of a payer or society. The realities of our
payment system force entities to respond in ways that are not
always perfectly aligned with societal needs, but publicly
reported measures should reflect the interest of society or
disclose clearly the perspective they represent.
Efficiency measures should include a clear statement of the
time horizon, with an acknowledgment of any limitations that
result from the time horizon chosen. In the usual course of
measurement, it will not be possible to provide the time
horizon necessary to determine with certainty whether a
larger short-term investment leads to a better long-term
outcome, even if the short-term outcomes are worse or
neutral. For example, bypass surgery provides upfront costs
and risks that may be offset by longer-term gains. A longer
length of stay for patients with heart failure could decrease
readmissions or reduce the need for skilled nursing facilities.
Thus, the time horizon needs to be clear and justified to the
extent possible. The cost assumptions made with the time
horizon used should be clear (eg, discounting).
Efficiency measures commonly include resources used in
the form of direct healthcare costs that ignore indirect costs.
The quantification of costs in efficiency measures presents
particular challenges. First, the methods of tabulating costs
and resources should be clear, reproducible, and appropriate.
If resource utilization is translated into costs, then the
approach should be stated clearly. If discounting of future
costs is included, then the approach should be stated and
justified. Charges (which are list prices) should be avoided
because they usually do not reflect costs or expenditures
accurately. Similarly, payer costs, which often reflect variable
negotiated rates with providers, should be avoided because
they are not standardized across payers. All calculations
should be stated explicitly.
The scope of the costs and resources should be stated and
justified. Considerable attention has been paid to this issue in
the cost-effectiveness literature, and the recommendations
from that literature should be followed if the form of the
measure lends itself to that approach by explicitly measuring
costs and outputs (22). An optimal measure of this type would
take a comprehensive approach to measuring cost. Failure to
do so could result in misleading conclusions. For example, a
narrow spectrum of measurement can result in calculations
that miss important costs that are just beyond the boundary of
the measure. Indeed, Hsu and others (23) revealed that drug
cost sharing can substantially lower drug costs but with an
increase in the risk of an emergency department visit, hospital
admission, and death. The net increase in total medical costs
was 1%. Thus, a measure that concerned itself solely with
drug costs would ignore the effect of that policy on patient
outcomes and costs in other areas. In another example,
Kosiborod and others (24), reporting on trends in the care of
hospitalized patients with heart failure in the 1990s, found
that dramatic decreases in length of stay were associated with
marked increases in readmission rates and discharge to
skilled nursing facilities, which could offset the cost savings
from a shorter length of stay. A focus solely on length of stay
would ignore the overall impact on resource consumption.
Risk adjustment is a critical component of cost estimates,
as it is with outcomes measurement, and should account for
differences in case mix across units of comparison. Methods
of risk adjustment need to be appropriate given the sample
size and unit of observation and may include hierarchical
modeling and attention to skewed distributions of outcomes
and costs. The statistical precision of estimates must also be
reported. Although appropriate analysis of the data was
highlighted in the prior report on outcomes measures (1),
there are additional considerations in models that use costs.
Again, the lessons from the cost-effectiveness and economet-
rics literature are useful.
No or Minimal Incentive to Provide
Poor-Quality Care
Any measure of efficiency should have no or only a minimal
incentive to provide poor-quality care; that is, the measure
should not have a perverse incentive such that excelling in the
measure could, from a more comprehensive viewpoint, ad-
versely affect patients and the healthcare system. The overall
intent of most efficiency measures should be to provide an
opportunity to improve the value of healthcare delivery by
eliminating waste and possibly reducing costs where they are
not justified on the basis of gains in the quality and appro-
priateness of care. If costs alone are targeted, then reductions
in cost may be associated with worse quality of care delivery
and adverse patient outcomes. For example, as described
above, a measure that captures only length of stay for a heart
failure admission could lead to practices of premature dis-
charge from the hospital, which is subsequently associated
with a higher rate of readmission. Such a result could, from a
broader perspective, worsen care and increase cost. The
incentive to do well on this measure is not necessarily aligned
with the best interests of patients or the healthcare system.
This measure needs to be combined with other measures to
avoid this problem.
Thus, efficiency measures should define how high perfor-
mance on the measure contributes to insights that will lead to
improvements in healthcare delivery, with particular attention
to the effect on individual patients and society. If performing
well on the measure could have a markedly negative effect on
patient outcomes or provide incentives that are counter to
high-quality care, then the efficiency measures could per-
versely affect patients and society, because they push expen-
1521JACC Vol. 52, No. 18, 2008 Krumholz et al.
October 28, 2008:1518–26 Standards for Measures: Efficiency in Health Care
ditures away from areas in which they produce economically
attractive results. Thus, it is crucial for an efficiency measure
to be developed with explicit attention given to how improve-
ments in what is measured would reflect improvement in
healthcare delivery from a societal perspective.
One approach to minimizing unintended consequences is to
develop a battery of complementary measures of cost and
quality so that the tradeoffs are explicit, as in a balanced
scorecard (25–28). In the example above, it may be useful to
include length of stay after a heart failure hospitalization if that
measure is combined with other measures of patient outcomes,
such that it would be clear whether a reduction in length of stay
worsened patient outcomes. In this approach, high performance
could be achieved only if length of stay were reduced and patient
outcomes did not change or even improved. It might even be
better to include a more explicit measure of cost of the
hospitalization and the outpatient transition along with patient
outcomes. In this case, investment in disease management and
the transition to outpatient status would be captured, as would
the result of that investment.
The avoidance of perverse incentives does not necessarily
mean that measures cannot discourage certain investments,
even if they reduce patient outcomes. There are limits to what
can be spent to promote patient outcomes. There may be
some interventions that are so expensive that they make the
health benefit economically unattractive for the healthcare
system. At the margin, a measure could provide an incentive
to eliminate such a high-cost investment, with the conse-
quence of some diminution of health benefit. It is necessary to
see the larger picture to determine whether resources are
allocated wisely to produce high-quality care. The point is
neither to maximize quality regardless of cost nor to mini-
mize costs regardless of the effect on quality. Rather, the aim
is to provide information that allows for the evaluation of any
tradeoffs between cost and quality. At some point, costs for a
strategy may be so high that they do not justify the better
outcomes, or cost savings may be so poorly placed that they
cause an unreasonable diminution in patient outcomes. With-
out both measures, these assessments cannot be made.
Because potential adverse effects may not be anticipated,
an explicit plan for evaluation of the impact of efficiency
measures should be used, particularly with regard to measur-
ing impact on patients (including their health status), systems
of care, and society. Although it may not be possible to
demonstrate convincingly that a proposed efficiency measure
will not have an adverse effect on patients, it is nevertheless
important to address potential unintended consequences. For
example, there is still debate about whether the publication of
cardiac surgery report cards led to surgeons avoiding operat-
ing on higher-risk patients (29,30). To mitigate concerns that
an efficiency measure might lead to decreased costs at the
expense of decreased quality, one could also present a direct
measure of quality, such as patients’ survival and health
status for a discrete follow-up period before and after imple-
mentation of the publicly reported measure. In any case, such
a possibility should be considered in the development and
assessment of the measure.
The issue of tradeoffs is not present for all practices in
medicine, and at this stage, these measures might best be
directed where there are opportunities to decrease cost with-
out an adverse effect on quality and outcomes, or even with
an opportunity to improve care. An example of a measure
with minimal potential adverse effects would be an assess-
ment of the number of tests performed that have been deemed
inappropriate by an American College of Cardiology Foun-
dation expert consensus panel. These panels have addressed
the appropriateness of cardiovascular tests and procedures
and identified indications of appropriateness (18 –20). These
indications were developed to identify groups of patients who
would not benefit from these tests or procedures. Elimination
of these expenditures might even enhance patient outcomes.
No measure would be expected to be free from the possibility
of an adverse consequence. In addition, we cannot protect
against a few unscrupulous individuals putting their performance
on the measure above the interests of patients. Nevertheless,
what is important is that this issue be considered and that the
measures not strongly encourage such practices.
Proper Attribution of the Measure
Proper attribution, which is relevant to all performance mea-
sures, involves correctly assigning the measure to the individual,
group, or organization responsible for the decisions, costs, and
outcomes. Attribution is often difficult when patients see many
practitioners, particularly when an “episode of care” is used to
incorporate costs accumulated over a specified time horizon and,
in the case of efficiency measures, when those responsible for
costs may not completely overlap with those responsible for
quality. The assignment of responsibility to any single person
may be difficult even in cases in which there is a single leader of
the effort, such as may occur with surgery. The surgeon may
perform the procedure, but the costs and outcomes are still
related to the sum of efforts by many individuals who care for
the patient and are influenced by the system in which the care
takes place. In the case of 30-day readmission rates for patients
discharged with heart failure, the attribution to hospitals may be
disputed because the time horizon crosses inpatient and outpa-
tient settings. For costs from a payer’s perspective, even when
practitioners make decisions that affect costs, the attribution may
be shared with others, because the price of the resources may be
negotiated by others and outside their control.
The fact that no single provider was acting alone should not
deter measurement, but the procedure for attributing the measure
should be stated clearly and justified. The complexities of
attribution are best acknowledged explicitly, because it will be
rare for costs and outcomes to be easily attributed to a single
person, entity, or even healthcare system.
Moreover, the shared nature of attribution of care provides
an opportunity for measures to be understood as providing an
incentive for increased collaboration across the provision of
health care. From the patient perspective, the responsibility
for care resides with all the people and institutions that were
part of that care. This collective attribution might lead to
greater cooperation in the service of the patient and health-
care system, although it is not known whether this result can
be achieved in practice.
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Conclusions and Recommendations
The implementation of efficiency measures to induce more
appropriate and judicious use of healthcare resources is
important and challenging. Changing practice to benefit
patients and society will require rigorous measures that
capture opportunities to improve the efficiency and value of
health care. These measures will reflect the resources used
and the results obtained.
To protect the interests of patients while illuminating the
efficiency of care, it is critically important to create measures
that will improve the healthcare system. Measures that reliably
expose inefficient care may facilitate internal efficiency im-
provement and drive patients to more efficient providers. Costly
care is not necessarily inefficient care, and confusing the two
may lead to a worsening of clinical care and a waste of
resources. For example, an emphasis on restraining costs without
consideration of the consequences could markedly undermine
health outcomes and lead to higher future costs.
With the present statement, we suggest 4 domains that
should be considered in any effort to measure and publicly
report efficiency. Measures that comply with these standards
will be a first step that requires the accompaniment of system
changes that encourage practices that are fiscally responsible
and oriented toward the best interests of patients and society,
with the recognition that these interests are not always
aligned. Table 2 shows how some sample measures may be
assessed by each of these domains. The measures that are
most aligned with these standards are those that target
practices that raise costs and have an adverse or neutral effect
on outcomes, as seen in the example about inappropriate
imaging. Those measures in areas where cost can be con-
strained, but at the risk of adversely affecting patient
outcomes, require explicit examination in the public do-
main with a clear view of the tradeoffs that may be made
in the spirit of more efficient healthcare delivery. These
are cases in which the interests of payers, patients, and
society can diverge or in which unintended consequences
can cause inadvertent harm.
In sum, the present document provides a framework for the
development and evaluation of efficiency measures. This
statement does not propose measures or set firm criteria that
measures must pass but identifies domains that need to be
addressed as measures are proposed and implemented. In all
of these efforts, it will be important to conduct evaluations to
assess the impact of implementation and to document the
result from the perspective of patients and society.
Table 2. Examples of Hospital-Based Measures and Their Properties According to the Standards
Standards and Assessment
Measure Integration of Quality and Cost
Valid Cost Measurement and
Analysis
Minimal Incentive to Provide
Poor-Quality Care
Proper Attribution of the
Measure
Length of stay No: Length of stay is a measure
of utilization with only an
indirect association with quality
N/A No: Incentive to lower length
of stay could lead to
premature discharge and
adverse events, including
higher overall costs
Yes: Attribution to the hospital
is appropriate
30-Day readmission Yes and no: Readmission
indirectly incorporates
considerations of cost and
quality; however, cost of initial
care is not included, and if
extra resources were required
to reduce readmissions, a
singular focus on readmission
would miss it
N/A Yes and no: Incentive to
reduce readmissions could
lead to behaviors that
reduce access to the
hospital for those who were
recently discharged
Yes: Attribution to the hospital
is appropriate, although there
are also outpatient factors
that are important
Hospitalization costs No: A singular focus on cost
does not include consideration
of quality
Yes and no: Depends on
methodology
No: A focus on cost may
lead to incentives to reduce
necessary services and
increase risk for adverse
consequences for patients
Yes: Attribution to the hospital
is appropriate
Nonrecommended imaging
tests
Yes: Unnecessary tests are
costly and represent
poor-quality care
N/A Yes: Incentive is to avoid
unnecessary testing
Yes: Attribution to the hospital
is appropriate
N/A indicates not applicable.
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